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Abstract
This chapter covers the basic knowledge on interactions between the central nervous
system and immunity. It presents information about the main factors and mecha‐
nisms that refer to the traditional and new concepts on immune privilege of the brain.
In addition, the immune surveillance and tolerance are discussed in context of the
central nervous system homeostasis, production of autoreactive lymphocytes, and
neurons vulnerability.
Certain general aspects in principles of positron emission tomography (PET) techni‐
que, radiotracer characteristics, and specificities of the cerebral glucose uptake are
provided. The chapter also offers an overview of the current clinical application of
(18F)-FDG PET imaging in the detection and differential diagnosis of different auto‐
immune disorders of the central nervous system.
This chapter reviews the autoimmune underlying mechanisms and main abnormali‐
ties in cerebral glucose metabolism in patients with multiple sclerosis, late-onset atax‐
ias, and limbic encephalitis. Own clinical observations and results are presented in
accordance to previous publications. Neuroimaging findings are discussed in context
of PET sensitivity and accuracy for assessment of disease localization and characteri‐
zation.
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1. Introduction
1.1. Central nervous system and immunity
Advances in scientific research and accumulated working knowledge of anatomo-functional
subsystems of the central nervous system (CNS) and their relationship with the downregula‐
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tion of the immune system play a crucial role in the understanding of underlying mechanisms
and treatment of immune-mediated neurological disorders [19, 37].
Traditionally, CNS is considered an immunologically-privileged site, meaning the brain and
spinal cord can tolerate the introduction of foreign antigens without eliciting an afferent
immune response [29, 34]. Immune privilege is believed to be an active process aiming to
protect the brain structures from the harming effect of an inflammation. This immune privilege
is thought to be due to a lack of lymphatic drainage and the integrity of blood-brain barrier
(BBB) [21]. It varies throughout the different parts of the CNS, being most pointed in the white
matter. Among the other factors that also contribute to the maintenance of brain immune
privilege are local production of immunosuppressive cytokines, increased expression of
surface molecules inhibiting complement activation, low expression of major histocompati‐
bility complex (MHC) class Ia molecules, presence of neuropeptides, etc. [26].
Over the last two decades the concept of CNS as an immunologically-privileged site has been
reevaluated. Today, experimental and clinical data show evidence suggesting the presence of
resident CNS macrophages known as microglia [42]. Although the separation and isolation of
CNS from the peripheral immune cells throughout the BBB, certain unique interactions exist
due to the sequestration of neuronal antigens in “partially” immune-privilege sites, presence
of antigen determinants shared by the nervous and immune systems, and secretion of
immunoregulatory mediators by specific nerve cells [19, 29, 34]. Nowadays, it is known that
activated lymphocytes are able to pass through the BBB regardless of their antigen specificity,
directed by cytokines and adhesion molecules that are expressed on the brain endothelial cells
(ICAM-1, VCAM-1) [2]. Normally, MHC class 1 and class 2 molecules are minimally expressed
in the CNS, but in pathology the expression induced by proinflammatory cytokines IFN-γ is
much higher. Immune surveillance in the CNS is under strong control and its major role is to
provide constancy of the homeostasis in relation to the raised vulnerability of the neurons [26].
Immune tolerance is known to protect normal tissues from immune damage by prevention of
immune response against a particular antigen to which the human organism is normally
responsive. In the past, it was thought that the break of immune tolerance causes the produc‐
tion of autoantibodies and/or sensitized cytotoxic T-lymphocytes, attacking own tissues, the
so-called autoreactive lymphocytes. Today, it is evident that these autoreactive cells normally
exist in the immune system in a state of anergy and areactivity toward own antigens. Respec‐
tively, the immune tolerance is considered as a result from suppression and elimination of
autoreactive T-lymphocytes [2].
It is known that autoimmunity represents an abnormal immune response directed against the
cells and tissues of the organism. Autoimmune responses are considered an integral part of
the immune system and present a survival self-defense mechanism. It is postulated that this
aberrant immune response refers to the development of different diseases. The mechanisms
of autoimmune disorders of the CNS are associated with molecular mimicry, upregulation of
heat shock proteins, the release of so-called “sequestrated” antigens (brain tissue antigens
hidden behind the BBB), bystander activation, and production of neoantigens [13, 42]. Most
commonly T- and B-cell mediated autoimmune diseases result from the elimination and
inhibition of regulatory T-cells or the dysregulation of humoral immunity.
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2. Positron emission tomography in neurology
In recent years, a large number of scientific reports confirm the increasing influence of nuclear
medicine in the diagnosis and treatment of patients with various neurological diseases [10, 23,
25, 33, 43]. Accordingly, positron emission tomography presents a modern non-invasive
technique for investigation in vivo of basic biochemical processes and physiological functions
of the CNS [36]. This method provides important information about the cerebral blood flow,
permeability of BBB, activity of brain enzymes, and metabolism of glucose, amine and fatty
acids, as well as synthesis and metabolism of neurotransmitters, gene expression and density
of neuromediators receptors.
PET has a wide clinical application in the understanding of underlying mechanisms of
neurological diseases, early and correct diagnosis, monitoring of clinical course and prognosis
of outcome, studying of drugs pharmacokinetics and pharmacodynamics, and assessment of
therapeutic response. In addition to structural neuroimaging, PET improves the diagnostic
accuracy of localization, characterization, and distribution of anatomical and functional
cerebral disturbances [17, 33, 36].
PET is realized through intravenous injection of radiotracer, which is a biological marker,
labeled with positron emitting isotope [7]. Carbone (11C), nitrogen (13N), oxygen (15O), and
fluorine (18F) are among the most frequently used in clinical practice due to their relatively
short  half-life  (up  to  110  min)  and  constant  body  spread,  without  prolonged  radiation
exposure [40].
It is well known that the human brain presents only 2% of body weight, but utilizes about 20%
of absorbed oxygen and 60% of glucose, which is a major energy source for the nerve cells.
Respectively, (18F)-FDG is the most appropriate radiotracer for functional study of cerebral
tissue, because it reflects the level of glucose assimilation by brain neurons. 18F-Fluorodeoxy‐
glucosae - (18)FDG represents deoxyglucosae that is labeled with 18F. FDG is a glucose
analogue that biodistribution fully reflects the glucose consumption of different organs and
tissues [44]. Its cell’s influx is realized through active transport, by means of glucose trans‐
porters in mechanisms that are similar and competing with glucose. After entering the cytosol,
the molecule is phosphorylated into a stable form, which has a slower metabolism and
prolonged cell’s retention than glucose.
The brain tissue is characterized by high glucose activity, mainly in the cortical, thalamic,
cerebellar, and basal ganglia gray matter, and relatively lower in the white matter [23]. The
distribution in the cerebral cortex is not homogeneous, as the highest activities are realized in
the occipital lobes.
New data support the notion that PET is a useful technique for diagnosis, planning treatment,
and prognosis in various neurological diseases, including autoimmune disorders of the CNS
[3, 8, 24]. By measuring brain and spinal cord metabolism, FDG-PET may demonstrate
extensive regions of neurologic dysfunction in patients with multiple sclerosis (MS), immune-
mediated cerebellar ataxias and autoimmune limbic encephalitis [4, 10, 15, 33, 41].
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3. PET in diagnosis of autoimmune neurological disorders
3.1. Multiple sclerosis
MS is an immune-mediated inflammatory, demyelinating disease of the CNS [22]. The etiology
is not known, but it is supposed to involve a combination of genetic predisposition and certain
triggers (e.g., various viral infections, low vitamin D levels) that cause recurrent immune
attacks [28]. MS is supposed to be associated with certain genetic loci, which are known to
influence the regulation of the immune system and higher susceptibility to this autoimmune
disease [12]. Strong relationship exists with class II alleles (HLA-DR2, HLA-DR15), T-cell
receptor gene, genes synthesizing immunoglobulins, tumor necrosis factor-α (TNF-α), and
myelin basic protein (MBP).
MS is an inflammatory disease of the CNS characterized by the dissemination lesions of
demyelination, called plaques, in the brain and spinal cord [32]. The main pathological changes
include the degeneration of axons, astrocytes-induced gliosis, and sclerosis [22]. The stepwise
lesion formation enlists the activation of myelin-reactive T cells in the periphery, breakdown
of the BBB, penetration of activated inflammatory cells (lymphocytes and macrophages), and
B-cell activation (generation of antibodies to MBP). Evidence exist that MS plaques are
associated with expression of high levels of Interleukin (IL)-12 and B7-1, stimulating the release
of proinflammatory cytokines [28]. Functionally-decreased T-lymphocytes with regulatory
role (Tregs), microglia, dendritic cells, natural killer (NK) cells, and nonimmune (endothelial)
cells are also involved in the mechanisms of CNS inflammation.
MS is diagnosed on the basis of clinical findings, brain magnetic resonance imaging (MRI),
and cerebrospinal fluid examination (CSF) [31, 32]. Additionally, (18F)-FDG PET scans reveal
the localization and distribution of cerebral hypometabolism in relation to demyelinating
lesions in the white matter and their remote influence over the glucose metabolism of cortex,
basal ganglia, and cerebellum [5, 10]. This method is also useful in MS patients with cognitive
dysfunction for investigation of global and regional cerebral glucose metabolism in compar‐
ison to MRI findings [35]. According to Bakshi R et al. [3] and Derache N et al. [9], (18F)-
FDG PET scans have clinical application as a marker for assessment of disease activity and
response to immunotherapy. Although, cerebral imaging studies show variable results [6, 15,
16, 27], our (18F)-FDG PET findings in MS patients with certain cognitive impairment reveal
areas  of  hypometabolism,  corresponding  to  the  white  matter  lesions  and brain  atrophy
(Clinical case 1).
Clinical case 1. A 44-year-old male with relapsing-remitting MS and cognitive impairment.
Neuroimaging findings (Fig. 1, 2, and 3).
3.2. Autoimmune cerebellar ataxia
Late-onset progressive cerebellar disorders can result from various pathologic processes,
including malformations, degenerative and vascular disorders, infections, neoplasms,
paraneoplastic syndromes, toxic/metabolic disorders, and demyelinating disease [1]. It is
known that the immune system plays an important role in the development of paraneoplastic
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and nonparaneoplastic types of cerebellar ataxia [38]. Clinical data suggest that immune-
mediated cerebellar ataxia may be caused by autoantibodies to various cerebellar targets [39].
Anti-voltage-gated calcium channel (VGCC), -Yo (Purkinje cell antigen), -ANNA-3, -Ri, -Hu,
-Ma, -PCA-2, and -mGluR antibodies are found in patients with paraneoplastic cerebellar
ataxia. In contrast, nonparaneoplastic ataxia is associated with anti-GAD, -gliadin, and -
thyroid antibodies. Cross-reaction between tumor and cerebellar antigens is thought to be an
underlying mechanism of autoimmune paraneoplastic ataxia [33]. The detection of circulating
Figure 1. MRI shows MS lesions expressed in the left cerebral hemisphere.
Figure 2. (18F)-FDG PET reveals areas of hypometabolism related to MS lesions and brain atrophy expressed mainly in
the left cerebral hemisphere.
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autoantibodies in patients with nonparaneoplastic cerebellar ataxia supports the notion that
the immune system is also involved in the pathogenesis of these sporadic cases.
The diagnosis is usually suggested by the presence of atrophy of the cerebellum and brainstem
on computed tomography scans (CT) and magnetic resonance imaging (MRI) [1, 38]. In
addition, PET is useful in the investigation of patients with acute or chronic ataxias [33].
Functional neuroimaging with (18F)-FDG improves the detection of etiology and understand‐
ing of underlying pathophysiologic mechanisms in patients with late-onset cerebellar ataxia.
Certain investigations reveal a reduction in absolute values of regional cerebral glucose
metabolism in the cerebellar hemispheres and vermis, as well as in the brainstem or dentate
nuclei [24, 25]. We report similar (18F)-FDG PET observations on our patient with anti-Yo
antibody-positive late-onset cerebellar ataxia, associated with two different types of tumors
(Clinical case 2). In contrast, Wang P et al. [41] show various patterns of cerebral glucose
metabolism in patients with ataxia.
Clinical case 2. A 49-year-old female with skin melanoma and ovarian cyst in accordance with
autoimmune (paraneoplastic) cerebellar ataxia. (18F)-FDG PET findings (Fig. 4 and 5).
3.3. Autoimmune limbic encephalitis
Limbic encephalitis is a severe, neuropsychiatric disorder that affects the limbic system, which
is responsible for the basic autonomic functions [14]. Based on the etiology, it is divided into
two clinical forms: viral and autoimmune. The inflammation in the latter is caused by the
autoimmune process that involves medial temporal lobes. Autoimmune limbic encephalitis
(ALE) may be either paraneoplastic, which is associated with a large number of cancers (lung,
breast, testicular, thymoma, Hodgkin lymphoma) or idiopatic (non-paraneoplastic) [18, 20].
ALE can be associated with the presence of autoantibodies to two groups of antigens: intra‐
cellular neuronal and cell-surface [39]. The first group includes Hu, Mu2, Ri, glutamic acid
Figure 3. (18F)-FDG PET reveals areas of hypometabolism related to MS lesions and brain atrophy expressed mainly in
the left cerebral hemisphere.
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dexcarboxylase (GAD), amphiphysin, and collapsing responce-madiator protein 5. Voltage-
gated potassium channels (VGKC), N-methyl-d-aspartate receptor (NMDAR), α-amino-3-
hydroxy-5-methyl-4-isoxazoleproprionic acid (AMRAR) belong to the latter antigen group.
The diagnosis of ALE is based upon clinical features (memory loss, temporal lobe epilepsy,
and psychiatric syndrome), MRI, electroencephalography (EEG), and cerebrospinal fluid
analysis [14]. Cerebral (18F)-FDG PET studies describe different scan patterns in patients with
ALE [4, 8]. According to Fisher R et al. [11], one is specific to the disease and presents a
combination of pronounced occipital hypometabolism and hypermetabolism in the temporal
and orbitofrontal cortex. We describe the similar findings in one patient with idiopathic ALE
(Clinical case 3). The other pattern closely resembles a diffuse neurodegenerative disease. Rey
Figure 4. (18)F-FDG PET reveals strongly reduced metabolic activity in the cerebellum.
Figure 5. (18)F-FDG PET reveals strongly reduced metabolic activity in the cerebellum.
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C et al. [30] report three cases with non-paraneoplastic limbic encephalitis characterized by
(18F)-FDG PET bilateral striatal hypermetabolism, in contrast to diffused hypometabolism in
the rest of the brain.
Clinical case 3. A 35-year-young male with idiopathic autoimmune limbic encephalitis.
Neuroimaging findings (Fig. 6 and 7).
Figure 6. Coronal magnetic resonance-fluid attenuated inversion recovery (MRI-FLAIR) shows bilateral increased sig‐
nal of hypothalamus and amygdala.
Figure 7. The (18F)-FDG PET scan reveals the nonhomogeneous distribution of cortical metabolic activity with discreet
reduction in the left parietal region; hypermetabolism in both medial temporal lobes to hippocampi.
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4. Summary
Although there are recent advances in molecular and cellular neurobiology, achievements of
neurogenetics, and application of modern anatomical and functional neuroimaging techni‐
ques, the human brain is still an “enigma” and several immune-mediated inflammatory and
neurodegenerative diseases of the CNS remain diagnosed late and unsuccessfully treated.
Accordingly, a future research in basic neuroimmunology and innate mechanisms of autoim‐
munity is necessary to provide more precise immunodiagnostic assays and modern thera‐
peutic approaches in patients with neurological autoimmune diseases. Furthermore, the
development of new radiology methods and specific radiotracer biomarkers for the needs of
neuroinflammation and degeneration imaging is another serious precondition to guarantee
the early detection and adequate treatment of immune-mediated damages of the CNS.
Respectively, existing clinical data support the notion that PET scanning improves the medical
diagnosis, differentiation, monitoring, and prognosis of certain debilitating autoimmune
diseases that affect the brain and spinal cord tissue.
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